Moderna to build vaccine manufacturing facility in UK

WCN Editorial Team 22 Jun 2022 EUROPE BUILDINGS

Moderna has announced an agreement in principle with the UK government to build an mRNA Innovation and Technology Center in the country.

The mRNA vaccine-producing facility is anticipated to offer access to quick pandemic response capabilities and the company’s respiratory virus vaccine candidates.

Moderna plans to expand in the UK via investments in research and development (R&D) activities.

Moderna CEO Stéphane Bancel said: "We are excited to be able to continue our collaboration with the UK government and Vaccine Taskforce with this new mRNA Innovation and Technology Center in the UK. The UK has established a world-class life sciences and research community.
"We are committed to global public health, and as we continue to expand internationally, we are pleased to bring local mRNA manufacturing to the UK. We look forward to establishing our R&D activities and capabilities in the country."

Moderna anticipates its facility to manufacture mRNA vaccines, including vaccines against Covid-19, seasonal influenza, respiratory syncytial virus (RSV), and potential other vaccines

The facility is expected to be activated urgently to support the country’s quick pandemic response capabilities.

Moderna is collaborating with the National Institute for Health Research (NIHR) on a Phase 3 study to examine the company’s bivalent Omicron-containing booster candidate (mRNA-1273.214) .

Separately, the UK government bought 60 million doses of Moderna's Covid-19 vaccine, which may include authorised booster vaccine candidates for delivery this year and next year.
Image: Moderna anticipates its facility to manufacture mRNA vaccines. Credit: Arek Socha from Pixabay.

With 11 websites and newsletters covering all the key areas within the construction industry, World Construction Industry Network is the leading global construction information resource. READ ABOUT US



World Construction Network | is a product of GlobalData. Copyright © 2022 GlobalData. All rights reserved.